Clinical Trial

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2022-11-01; most recent amendment 2026-06-18.
Status change: Recruiting → Active, Not Recruiting 2026-06-18
Trial Details
NCT Number NCT05609578
Lead Sponsor Mirati Therapeutics Inc.
Conditions Advanced NSCLC, Metastatic Lung Cancer
Enrollment 90 participants
Start Date 2022-11-22
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-23